Nucleoside Reverse Transcriptase Inhibitors (nrtis) - Toxicology

Relevant Publications

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.

Issue Release: 2024

HIV-1 molecular networks and pretreatment drug resistance at the frontier of Yunnan Province, China.

Issue Release: 2024

Choice of antiretroviral therapy has low impact on weight gain.

Issue Release: 2024

Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed.

Issue Release: 2024

Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.

Issue Release: 2024

Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo.

Issue Release: 2024

Prevalence of acquired and transmitted HIV drug resistance in Iran: a systematic review and meta-analysis.

Issue Release: 2024

Retrospective Study on Genetic Diversity and Drug Resistance among People Living with HIV at an AIDS Clinic in Beijing.

Issue Release: 2024

HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde, 2019-2021.

Issue Release: 2024

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia.

Issue Release: 2024

High prevalence of pre-treatment and acquired HIV-1 drug resistance mutations among non-citizens living with HIV in Botswana.

Issue Release: 2024

Selected Milestones in Antiviral Drug Development.

Issue Release: 2024

Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China.

Issue Release: 2024

Severe Lactic Acidosis Due to Inappropriate Use of Biktarvy in a Patient With AIDS.

Issue Release: 2024

HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.

Issue Release: 2024

HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.

Issue Release: 2024

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved.

Issue Release: 2024

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review.

Issue Release: 2024

Reverse transcriptase inhibitors prevent liver abscess formation during bloodstream infection.

Issue Release: 2024

D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.

Issue Release: 2024

What is Cystoscopy?

How Do Toxicants Affect Energy Production?

Why is Gender-Specific Research Important?

What are the Research Directions in Sulfur Dioxide Toxicology?

What are the Challenges in Internal Proficiency Testing?

Are There Alternatives to Saline in Toxicology?

What Role Do Life Cycle Assessments Play?

What is the Role of Vaccination in Preventing Tetanus?

What are the Steps Involved in an Audit?

How Does OCT Work in Toxicology?

Partnered Content Networks

Relevant Topics